Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial

一项I期临床试验表明，生物调节节律疗法在IV期黑色素瘤患者中耐受性良好，并可能延长无进展生存期。